Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab in IgG4-related Disease
NCT04660565Phase 4Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jan 2021
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of belimumab in IgG4-related disease (IgG4-RD) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoints: Efficacy of Belimumab in reducing the risk of flare at 12 months and Difference of time to first flare between two groups at 12 months. Status: unknown.
02
Drugs
belimumab
03
Conditions
IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on NCT04660565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04660565.